

visiting the NCVHS website (<http://ncvhs.hhs.gov>) where an agenda for the meeting will be posted when available.

Additional information may be obtained by calling Carolyn Rimes, Lead Staff Person for the NCVHS Subcommittee on Populations, Office of Research and Demonstrations, Health Care Financing Administration, MS-C-13-01, 7500 Security Boulevard, Baltimore, Maryland, 21244-1850, telephone (410) 786-6620; or Marjorie S. Greenberg, Executive Secretary, NCVHS, NCHS, CDC, Room 1100, Presidential Building, 6525 Belcrest Road, Hyattsville, Maryland 20782, telephone (301) 458-4245.

**Note:** In the interest of security, the Department has instituted stringent procedures for entrance to the Hubert H. Humphrey Building by non-government employees. Thus, individuals without a government identification card may need to have the guard call for an escort to the meeting room.

Dated: December 21, 1999.

**James Scanlon,**

*Director, Division of Data Policy.*

[FR Doc. 99-33621 Filed 12-27-99; 8:45 am]

**BILLING CODE 4151-05-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Advisory Committee to the Director, Centers for Disease Control and Prevention: Meeting.

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following Advisory Committee meeting.

*Name:* Advisory Committee to the Director, CDC.

*Time and date:* 8:30 a.m.—4 p.m., January 20, 2000.

*Place:* The Wyndham Garden Hotel, 125 10th Street, Atlanta, Georgia 30309.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 25 people.

*Purpose:* The committee will anticipate, identify, and propose solutions to strategic and broad issues facing CDC.

*Matters to be Discussed:* Agenda items will include updates from Dr. Jeffrey P. Koplan, M.D., M.P.H., Director, CDC, regarding the Top 10 Public Health Challenges for the Next Century.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Kathy Cahill, Executive Secretary, Advisory Committee to the Director, CDC, 1600 Clifton Road, NE, M/S D-24, Atlanta, Georgia 30333. Telephone 404/639-7060.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for

both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: December 17, 1999.

**Carolyn J. Russell,**

*Director, Management Analysis and Services Office Centers for Disease Control and Prevention.*

[FR Doc. 99-33560 Filed 12-27-99; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

#### Federal Allotments to States for Social Services Expenditures, Pursuant to Title XX, Block Grants to States for Social Services; Revised Promulgation for Fiscal Year 2000.

**AGENCY:** Administration for Children and Families, Department of Health and Human Services.

**ACTION:** Notification of allocation of title XX—social services block grant allotments for Fiscal Year 2000.

**SUMMARY:** The initial **Federal Register** notice was published on November 10, 1998 based on the authorization level of \$2.380 billion. The grant awards for Fiscal Year 2000 will be issued based upon the appropriation amount of \$1.775 billion. Of this amount, \$425,000,000 shall not be available for obligation until September 29, 2000. These figures are available on the ACF homepage on the internet: <http://www.acf.dhhs.gov/programs/ocs/ssbg>.

Further notification of revised allotments for SSBG will no longer be published in the **Federal Register**, but will be available on the internet address given above.

**FOR FURTHER INFORMATION CONTACT:** Margaret Washnitzer, (202) 401-2333.

**EFFECTIVE DATE:** The allotments are effective October 1, 1999.

Dated: December 20, 1999.

**Donald Sykes,**

*Director, Office of Community Services.*

[FR Doc. 99-33533 Filed 12-27-99; 8:45 am]

**BILLING CODE 4184-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Establishment of Prescription Drug User Fee Rates for Fiscal Year 2000

**AGENCY:** Food and Drug Administration.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the rates for prescription drug user fees for fiscal year (FY) 2000. The Prescription Drug User Fee Act of 1992 (the PDUFA), as amended by the Food and Drug Administration Modernization Act of 1997 (the FDAMA), authorizes FDA to collect user fees for certain applications for approval of drug and biological products, on establishments where the products are made, and on such products. Fees for applications for FY 2000 were set by the FDAMA, subject to adjustment for inflation. Total application fee revenues fluctuate with the number of fee-paying applications FDA receives. Fees for establishments and products are calculated so that total revenues from each category will approximate FDA's estimate of the revenues to be derived from applications.

#### FOR FURTHER INFORMATION CONTACT:

Michael E. Roosevelt, Office of Financial Management (HFA-120), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5088.

#### SUPPLEMENTARY INFORMATION:

##### I. Background

The PDUFA (Public Law 102-571), as amended by the FDAMA (Public Law 105-115), establishes three different kinds of user fees. Fees are assessed on: (1) Certain types of applications and supplements for approval of drug and biologic products, (2) certain establishments where such products are made, and (3) certain products (21 U.S.C. 379h(a)). When certain conditions are met, FDA may waive or reduce fees (21 U.S.C. 379h(d)).

For FY 1998 through 2002, under the amendments enacted in the FDAMA, the application fee rates are set in the statute, but are to be adjusted annually for cumulative inflation since FY 1997. Total application fee revenues are structured to increase or decrease each year as the number of fee-paying applications submitted to FDA increases or decreases.

Each year from FY 1998 through 2002, FDA is required to set establishment fees and product fees so that the estimated total fee revenue from each of these two categories will equal the total revenue FDA expects to collect from application fees that year. This procedure continues the arrangement under which one-third of the total user fee revenue is projected to come from each of the three types of fee: Application fees, establishment fees, and product fees.

This notice establishes fee rates for FY 2000 for application, establishment, and